EMA's electronic pilot
The EMA has launched a pilot for submitting centralised marketing authorisation applications electronically. The pilot began
on Monday 12 March and is expected to run for four months. During this period, companies will be able to apply for initial
marketing authorisation applications for human medicines, and variation and renewal applications for human and veterinary
medicines using an interactive PDF form.
According to the EMA, the pilot is a step towards using electronic applications as standard, using the Electronic Common Technical
Document (eCTD) format. Electronic applications are expected to simplify and accelerate the application process by improving
data quality and consistency during data entry, providing access to data in XML format and integrating application data with
Don Farrall/Digital Vision/GettyImages
Depending on the success of the pilot, the PDF forms may become an alternative — and the recommended — format for submitting
eCTD applications to the EMA. The forms were developed in collaboration with the EMA, European Commission services and medicines
regulators in EU member states, and their content is identical to that of the current application forms published by the European
Commission in EudraLex Vol. 2.
Companies wishing to participate in the pilot are being encouraged to register their interest so that they will receive any
urgent updates. Details on how companies can take part are described in the EMA's Electronic Application Forms Pilot Guidance, available on the EMA website:
Eli Lilly invests in bio facility
Eli Lilly plans to invest €330 million at its Kinsale location in Ireland to create a new biopharmaceutical commercialisation
and manufacturing facility. The investment will lead to 200 new jobs, as well as an additional 300 construction roles during
the building process.
The facility is planned to be approximately 24,000 ft2 and will produce treatments for illnesses such as cancer and diabetes. In a press release, Lilly's senior vice-president
of global API and dry product manufacturing, Paul Ahern said, "This investment is part of Lilly's planned growth strategy
and proof of our confidence in Lilly's pipeline of new products, many of which are derived from biotechnology."
Eli Lilly first established its presence in Kinsale in 1981 and the facility makes APIs for several of the company's products.
The latest announcement marks the second significant investment that the company has made at the site in recent years. In
2006, the company committed to invest €300 million in a biopharmaceutical and new-product commercialization facility. The
new facility came on line in 2010, but is still undergoing start-up activities. It is expected to manufacture commercial products
in late 2013.
Ireland's investment agency, IDA Ireland, worked closely with Lilly to attract the investment. According to Ireland's Minister
for Jobs, Enterprise, and Innovation, Richard Bruton, the government has recently outlined a range of measures that will be
taken in 2012 to target high-end manufacturing and the health and life science sectors for growth and job creation.
Several other pharmaceutical companies have invested in Ireland recently. Most recently, Abbott Laboratories announced an
€85-million investment at its manufacturing facility in Sligo at the beginning of February 2012. In September 2011, Pfizer
and Merck & Co. invested €145 million and €100 million in Irish pharmaceutical operations, respectively.